904326-87-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Acetamidopyridine-5-boronic Acid Pinacol Ester, 97% is used as a synthetic reagent for the development of new quinolinequinone derivatives, which exhibit cytotoxic properties. These derivatives have potential applications as therapeutic agents against cancer, making 2-ACETAMIDOPYRIDINE-5-BORONIC ACID PINACOL ESTER, 97% a valuable intermediate in the discovery and synthesis of novel anticancer drugs.
Used in Antibacterial Applications:
In the field of antibacterial research, 2-Acetamidopyridine-5-boronic Acid Pinacol Ester, 97% is utilized in the synthesis of novel benzoxazinyl-oxazolidinones. These synthesized compounds have potential applications as antibacterial agents, contributing to the development of new treatments for bacterial infections and addressing the growing concern of antibiotic resistance.

InChI:InChI=1/C13H19BN2O3/c1-9(17)16-11-7-6-10(8-15-11)14-18-12(2,3)13(4,5)19-14/h6-8H,1-5H3,(H,15,16,17)

Upstream product

• 827614-64-2 2-aminopyridine-5-boronic acid pinacol ester 
• 108-24-7 acetic anhydride 
• 1072-97-5 5-bromo-2-pyridylamine 
• 142404-84-0 N-(5-bromo-6-methyl-pyridin-2-yl)-acetamide 
• 73183-34-3 bis(pinacol)diborane 
• 7169-97-3 N-(5-bromopyridin-2-yl)acetamide 
• 25015-63-8 4,4,5,5-tetramethyl-[1,3,2]-dioxaboralane 

Downstream Products

• 1251949-00-4 N-(5-(7-chloro-3-(2-chlorobenzyl)-1-(4-methoxybenzyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)pyridin-2-yl)acetamide 
• 1332448-72-2 5-(2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)phenyl)-N-methylpicolinamide 
• 1332448-95-9 N-(5-(2-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)phenyl)pyridin-2-yl)acetamide 
• 1332448-20-0 N-(5-(3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)phenyl)pyridin-2-yl)acetamide 
• 1332448-80-2 5-(3-(2,8-dimethyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)phenyl)-N-methylpicolinamide 
• 1415999-92-6 N-(5-(9-oxo-10-(3-(trifluoromethyl)phenyl)-9,10-dihydropyrido[3,2-c][1,5]naphthyridin-2-yl) pyridin-2-yl)acetamide 
• 1613168-67-4 2-{[4-(6-acetamidopyridin-3-yl)phenyl]amino}-N-[4-(piperazin-1-ylmethyl)-3-(trifluoromethyl)phenyl]acetamide 
• 1613168-50-5 2-{[4-(6-acetamidopyridin-3-yl)phenyl]amino}-N-{4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}acetamide 

Relevant academic research and scientific papers

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated

A universal acetyl-aminopyridine boric acid frequency alcohol ester preparation method

The invention belongs to the field of organic compound synthesis and provides a preparation method of commonly used acetamidopyridine boronic acid pinacol ester. The preparation method comprises the following steps: 1. with halogenated aminopyridine as a starting material, reacting with acetic anhydride in dichloromethane to obtain halogenated acetamidopyridine; and 2. with dioxane as a solvent, mixing the halogenated acetamidopyridine, potassium acetate and bis(pinacolato)diboron under the protection of nitrogen and adding a catalyst ferrocene palladium chloride to react at 60-100 DEG C for 18-24 hours, thus generating the acetamidopyridine boronic acid pinacol ester. The raw materials are convenient to directly purchase from the markets. The preparation method is simple, is convenient to operate, is high in yield and is convenient for industrial production.

A 2-amino-thiazole compounds (by machine translation)

The present invention relates to the technical field of pharmaceutical chemistry, particularly relates to a 2-amino thiazole compound or its pharmaceutically acceptable salts, its preparation method, and pharmaceutical compositions containing such compounds and its application in the preparation of antineoplastic. (by machine translation)

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, us

Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF

The present invention relates to a pyridonaphthyridine compound as represented by general formula (I), which has a dual PI3K and mTOR inhibition effect, and its pharmaceutically acceptable salt, stereoisomer and deuteride thereof, wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the specification; the present invention also relates to a method for preparing said compound, a pharmaceutical composition and a pharmaceutical formulation containing said compound, and uses of said compound in treating and/or preventing a proliferative disease and in the manufacture of a medicament for treating and/or preventing a proliferative disease.

THREE-RING PI3K AND/OR MTOR INHIBITOR

The present application relates to a compound as represented by general formula (I), a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, preparation method of the compounds, a pharmaceutical composition containing the compounds, uses thereof in the preparation of drugs for treating and/or preventing proliferative diseases, and a method using the compounds to treat and/or prevent proliferative diseases. R1, R2, R3, R4, R5, R6, X, A and B in the formula are as defined in the specification.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.